Are you Dr. Kamiya-Matsuoka?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 30 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Carlos Kamiya-Matsuoka, MD is a board certified neurologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Alabama, and Arizona. He is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
- University of Texas Medical Branch HospitalsResidency, Neurology, 2010 - 2013
- Texas Tech University HSC El PasoResidency, Internal Medicine, 2009 - 2010
- National University of San MarcosClass of 2007
Certifications & Licensure
- FL State Medical License 2021 - Present
- TX State Medical License 2015 - 2026
- WA State Medical License 2023 - 2026
- AZ State Medical License 2023 - 2025
- GA State Medical License 2023 - 2025
- LA State Medical License 2023 - 2025
- MS State Medical License 2023 - 2025
- American Board of Psychiatry and Neurology Neurology
- Join now to see all
Clinical Trials
- Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting Start of enrollment: 2017 Jan 20
Publications & Presentations
PubMed
- 1 citationsImmune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas.Pravesh Gupta, Minghao Dang, Shivangi Oberai, Simona Migliozzi, Rakesh Trivedi
Neuro-Oncology. 2024-12-05 - NRG-BN002: Phase I study of ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastoma.Andrew E Sloan, Kathryn Winter, Mark R Gilbert, Kenneth Aldape, Serah Choi
Neuro-Oncology. 2024-09-05 - 2 citationsAccelerated tumor progression after COVID-19 infection in patients with glioblastoma: A retrospective case-control study.Timothy A Gregory, Stephanie R Knight, Ashley E Aaroe, Kaitlin N Highsmith, Zachary C Janatpour
Neuro-Oncology Practice. 2024-08-01